Oct 14, 2026 06:04AM
Oct 14, 2026 06:03AM
Oct 14, 2026 06:01AM
Oct 14, 2026 06:00AM
Oct 8, 2026 07:06AM
Oct 5, 2026 08:48AM
Oct 2, 2026 07:30AM Verastem presents LGSOC drug data at IGCS 2026 meeting
Oct 2, 2026 07:30AM
Sep 28, 2026 04:10PM
Sep 24, 2026 08:31AM
Sep 24, 2026 08:30AM
Aug 6, 2026 04:01PM
Jul 28, 2026 04:01PM
Jul 28, 2026 04:01PM Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
Jul 22, 2026 04:01PM
Jul 22, 2026 04:01PM
Jun 23, 2026 04:01PM
Jun 23, 2026 04:01PM
Jun 17, 2026 07:31AM
Jun 17, 2026 07:30AM
Jun 16, 2026 04:01PM VERASTEM doses first patient in Phase 2 pancreatic cancer trial
Jun 16, 2026 04:01PM
Jun 15, 2026 04:01PM
Jun 9, 2026 02:00PM
Jun 3, 2026 04:01PM
Jun 3, 2026 04:01PM
May 8, 2026 07:30AM
May 7, 2026 04:01PM Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Apr 30, 2026 07:30AM
Apr 10, 2026 07:00AM
Apr 10, 2026 07:00AM
Mar 17, 2026 06:03PM
Mar 17, 2026 04:44PM
Mar 4, 2026 04:01PM
Feb 4, 2026 07:31AM Verastem Oncology reports $30.9 million in 2025 drug revenue
Feb 4, 2026 07:30AM
Dec 29, 2025 04:01PM
Dec 29, 2025 04:01PM
Dec 15, 2025 04:01PM
Dec 15, 2025 04:01PM
Nov 14, 2025 12:41AM
Nov 14, 2025 12:41AM Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
Nov 13, 2025 04:07PM
Nov 13, 2025 04:07PM
Nov 4, 2025 07:30AM
Oct 23, 2025 04:01PM
Oct 23, 2025 04:01PM
Oct 19, 2025 04:15AM
Oct 19, 2025 04:15AM Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
Sep 11, 2025 08:18AM

335,219 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All